Benzinga | Jan 8, 2021 04:58AM EST

SVB Leerink Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $125

SVB Leerink analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $197 to $125.